Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 99 of 79742 for:    subjects

Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01955304
Recruitment Status : Completed
First Posted : October 7, 2013
Last Update Posted : April 22, 2019
Sponsor:
Information provided by (Responsible Party):
Hutchison Medipharma Limited

Brief Summary:
This study will determine the effect of food on the pharmacokinetics (PK) of a single dose of 4mg fruquintinib in normal healthy subjects.

Condition or disease Intervention/treatment Phase
Food Effect of Fruquintinib in Health Subjects Drug: fruquintinib Phase 1

Detailed Description:

This study will be an open-label, randomized, two-period, crossover PK food effect study of fruquintinib administered orally at 4mg. Subjects will be screened for eligibility up to 14 days prior to entry into the study.

For each of 2 study periods, subjects will be admitted to the clinical research unit (CRU) on the day before dosing and fast overnight (approximately 10 hours). On the morning of dosing for each of the 2 study periods, subjects will receive a single oral dose of 4 mg fruquintinib in either the fasted or fed state. Subjects will remain at the CRU for at least 120 hours after administration of study drug for collection of serial blood samples for pharmacokinetic (PK) analysis and safety monitoring. Subjects will return to the CRU for safety assessment for up to 336 hours postdose.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Fruquintinib (HMPL-013) in Healthy Subjects
Study Start Date : June 2012
Actual Primary Completion Date : September 2012
Actual Study Completion Date : December 2012

Arm Intervention/treatment
Experimental: A-fasted dosing followed by fed dosing
Experimental: Fasted dosing of fruquintinib followed by fed dosing; Dosing in the fasted state followed by fed dosing
Drug: fruquintinib
Fruquintinib 4 mg capsule, 2 discrete single doses separated by 2-weeks
Other Name: HMPL-013

Experimental: B-fed dosing followed by fasted dosing
Experimental: Fed dosing of fruquintinib followed by fasted dosing; Dosing in the fed state followed by fasted dosing
Drug: fruquintinib
Fruquintinib 4 mg capsule, 2 discrete single doses separated by 2-weeks
Other Name: HMPL-013




Primary Outcome Measures :
  1. • To determine the effect of food on the PK of a single dose of 4mg fruquintinib in normal healthy subjects. [ Time Frame: Planned Enrollment/Screening Duration: Approximately 2 weeks. Length of Each Confinement: Approximately 7days prior to dose until approximately 120 hours postdose. Planned Study Conduct Duration: Approximately 6 weeks ]
    Blood samples for PK analysis of serum fruquintinib levels will be collected for a 2-week period following each of 2 doses.


Secondary Outcome Measures :
  1. • To assess the safety and tolerability of single doses of 4mg fruquintinib [ Time Frame: Planned Enrollment/Screening Duration: Approximately 2 weeks. Length of Each Confinement: Approximately 7days prior to dose until approximately 120 hours postdose. Planned Study Conduct Duration: Approximately 6 weeks ]
    Safety will be assessed by physical exam, clinical laboratory evaluations and ECGs.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males , between 18 and 45 years of age, inclusive.
  • Body mass index (BMI) within the range of 19 to 25 kg/m2, inclusive.
  • In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, and vital signs.
  • Adequate hepatic, renal, heart, and hematologic functions
  • Male subjects who are either sterile or agree to use, during the period from informed consent until 90 days following Study Completion, 1 of the following approved methods of contraception: a double barrier method (eg, male condom with spermicide, use by female sexual partner of an intrauterine device with spermicide, a female condom with spermicide, contraceptive sponge with spermicide, a diaphragm with spermicide, or use of a cervical cap with spermicide); a sterile sexual partner; a female sexual partner using an intravaginal system (eg,NuvaRing®); or a partner using an oral, implantable, transdermal, or injectable contraceptives.
  • Able to comprehend and willing to sign an informed consent form (ICF).

Exclusion Criteria:

  • Significant history or clinical manifestation of any significant metabolic/endocrine, allergic, dermatological, hepatic, renal, hematological, pulmonary, immune, cardiovascular, gastrointestinal, genitourinary, neurological, or psychiatric disorder(as determined by the Investigator).
  • History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator.
  • History of stomach or intestinal surgery, nephrectomy, cholecystectomy or resection that would potentially alter absorption and/or excretion of orally administered drugs as determined by the investigator (appendectomy and/or hernia repair may be allowed).
  • History or presence of an abnormal ECG, which, in the Investigator's opinion, is clinically significant.
  • Diagnosis of alcoholism or drug addiction within 1 year prior to Period 1 Check-in.
  • Participation in any other investigational drug study in which receipt of an investigational study drug occurred within 5 half-lives or 30 days, whichever is longer prior to informed consent.
  • Use of any prescription medications or products within 14 days prior to Period 1 prior to informed consent.
  • Use of any over-the-counter (OTC), non-prescription preparations (including vitamins, minerals, and phytotherapeutic, herbal, dietary supplements, or plant derived preparations) within 7 days prior to each study period Check-in.
  • Use of alcohol-, grapefruit-, Seville orange-, or caffeine-containing foods, juices, or beverages within 72 hours prior to each study period Check-in.
  • Use of known hepatic or renal clearance altering agents (eg, erythromycin, cimetidine, barbiturates, phenothiazines, or herbal/plant derived preparations such as St. John's Wort, etc.) for a period of 60 days prior to informed consent;
  • Poor peripheral venous access.
  • Donation of blood ≥ 250 mL from 30 days prior to informed consent until study completion, inclusive, or of plasma from 2 weeks prior to informed consent until study completion, inclusive.
  • Receipt of blood products within 2 months prior to Period 1 Check-in;
  • Blood pressure greater than 140/90 mmHg confirmed by repeat at Screening or at Period 1 Check-in.
  • Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01955304


Locations
Layout table for location information
China, Shanghai
Shanghai Xuhui Central Hospital
Shanghai, Shanghai, China, 200031
Sponsors and Collaborators
Hutchison Medipharma Limited

Layout table for additonal information
Responsible Party: Hutchison Medipharma Limited
ClinicalTrials.gov Identifier: NCT01955304     History of Changes
Other Study ID Numbers: 2012-013-00CH2
First Posted: October 7, 2013    Key Record Dates
Last Update Posted: April 22, 2019
Last Verified: May 2013